论文部分内容阅读
为研究化疗前后不同分期、不同术式大肠癌患者的免疫功能，应用流式细胞仪检测３９例大肠癌患者化疗前后Ｔ细胞表面６种抗原标志，并与良性病变患者进行对比分析。结果显示：ＤｕｋｅｓＡ期大肠癌患者化疗前ＣＤ３，ＣＤ４，ＣＤ４／ＣＤ８，ＣＤ１６高于对照组，ＣＤ８低于对照组（Ｐ＜０．０５）。Ａ，Ｂ，Ｃ期化疗前活化Ｔ细胞ＣＤ３＋／ＨＬＡ－ＤＲ＋高于对照组（Ｐ＜０．０５）；化疗后随着Ｄｕｋｅｓ分期的增高，ＣＤ３，ＣＤ４，ＣＤ４／ＣＤ８，ＣＤ１６，ＣＤ６９，ＣＤ３＋／ＨＬＡ－ＤＲ＋逐渐明显降低，ＣＤ８逐渐增高（Ｐ＜０．０１）。根治及姑切术后，化疗前姑切组ＣＤ４，ＣＤ４／ＣＤ８，ＣＤ１６，ＣＤ６９，ＣＤ３＋／ＨＬＡ－ＤＲ＋低于根治组（Ｐ＜０．０５），化疗后两组ＣＤ８，ＣＤ１６，ＣＤ６９相同。结论：化疗药物对大肠癌患者细胞免疫功能的损害，随分期增高而逐步加重，姑息性切除术后更应注意定期化疗。
In order to study the immune function of patients with colorectal cancer before and after chemotherapy with different stages, flow cytometry was used to detect the surface markers of T cells in 39 patients with colorectal cancer before and after chemotherapy, and compared with benign lesions. The results showed that CD3, CD4, CD4/CD8, and CD16 in patients with Dukes A colorectal cancer before chemotherapy were higher than those in the control group, and CD8 was lower than that in the control group (P<0.05). The number of activated T cells CD3+/HLA-DR+ before A, B and C chemotherapy was higher than that of the control group (P<0.05); after chemotherapy, the levels of CD3, CD4, CD4/CD8, CD16, CD69, CD3+ increased with the Dukes stage. /HLA-DR+ gradually decreased, and CD8 increased gradually (P<0.01). After radical and guillotine surgery, CD4, CD4/CD8, CD16, CD69, and CD3+/HLA-DR+ were lower in the untreated group than in the radical group (P<0.05). After chemotherapy, CD8, CD16, and CD69 were identical in the two groups. Conclusion: The damage of cellular immune function to chemotherapy patients with colorectal cancer is gradually aggravated with the increase of the stage. More attention should be paid to regular chemotherapy after palliative resection.